SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · Delayed Price · USD
-0.71 (-11.91%)
At close: Jan 26, 2022 4:00 PM
-0.01 (-0.25%)
After-hours:Jan 26, 2022 4:00 PM EST

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing immunotherapeutic human antibodies.

The company applies advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce human antibodies targeted at specific diseases, including infectious diseases, such as COVID-19 and influenza; immune system disorders, including type 1 diabetes and organ transplantation; and cancer.

Its DiversitAb platform is applicable to a range of human diseases. The company was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SAB Biotherapeutics Inc.
CountryUnited States
SectorHealth Care

Contact Details

2100 East 54th Street North
Sioux Falls, SD 57104
United States
Phone605 679 6980

Stock Details

Ticker SymbolSABS
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1833214

Key Executives

Dr. Eddie Joe Sullivan Ph.D.Co-Founder, President, Chief Executive Officer and Director
Dr. Edward D. Hamilton D.V.M.Co-Founder and Board Observer
Christine E. Hamilton M.B.A.Co-Founder and Independent Director
Thomas Charles Luke M.D.Chief Medical Officer
Samuel J. ReichExecutive Chairman
Russell P. Beyer C.M.A.Chief Financial Officer
Dr. Kipp Erickson Ph.D.Chief Operating Officer
Christoph Bausch Ph.D.Chief Science Officer
Melissa UllerichChief Corporate Communications and Investor Relations Officer
Jerry Pommer M.Sc.Chief Compliance Officer

Latest SEC Filings

Jan 10, 20228-KCurrent report
Jan 6, 20228-KCurrent report
Dec 29, 2021424B3Prospectus [Rule 424(b)(3)]
Dec 16, 2021EFFECTNotice of Effectiveness
Dec 13, 2021CORRESPCorrespondence
Dec 8, 2021UPLOADSEC-generated letter
Dec 3, 2021S-1General form for registration of securities under the Securities Act of 1933
Nov 24, 20214/AStatement of changes in beneficial ownership of securities
Nov 22, 20218-K/ACurrent report
Nov 22, 202110-QQuarterly report [Sections 13 or 15(d)]
View All SEC Filings